According to a Dec. 4 news release, the technology, approved by the FDA in February, is able to prevent the backflow of blood in the upper-right chamber of the heart, known as tricuspid regurgitation. Haidar Yassin, MD, an interventional cardiologist said that about 1.6 million people in the U.S. deal with moderate to severe forms of tricuspid regurgitation, which can be life-threatening or life-shortening.
“Through this treatment, we can improve quality of life, relieve symptoms such as tiredness, shortness of breath and fatigue,” Dr. Yassin said.
Dr. Yassin spearheaded the effort alongside Robert Riley, MD, the network director of cardiothoracic surgery at HonorHealth Heart Care.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
